Dong-A Pharmaceutical Co., Ltd., a subsidiary of Dong-A Socio Holdings Co., Ltd., is a company headquartered in Seoul, the South Korea, that manufactures drug products.

EDDA Technology offers computer assistance to the patient care management cycle and enables early detection and diagnosis of diseases. The company developed the IQQA platform that provides innovative imaging solutions to physicians, enabling improved workflow and patient care in open/minimally invasive/robotic surgery. It encourages a patient-specific, disease-targeted, multidisciplinary approach to cancer treatment. The end-to-end surgical enabling platform supports pre-surgical planning and simulation, intra-operative guidance and monitoring, post-operative follow-up evaluation, and training.

Hangzhou Zhenhe Health Technology Co., Ltd., established on 2019-07-11, Business scope includes non-medical health information consultation;medical technology,medical technology,Biotechnology,IoT technology,Internet information technology,computer network Technology,multimedia technology,Games software,data processing technology,Computer hardware and software,educational software,Technology Development of Computer System Integration,Technical Services,technical consulting,Achievement transfer;Sales:Class I medical device,Disinfectant,cosmetic(Repacking),electronic product,clothing;Pension Service(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Biovail Laboratories, Inc., a subsidiary of Bausch Health Cos., Inc., is a Canadian company. The firm provides clinical testing and drug development services.

Shandong Shanwei Immune Technology Co., Ltd., established on 2020-12-29, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Research and development of bio-based materials technology;Manufacturing of bio-based materials;Sales of bio-based materials;Natural science research and experimental development;Food Additive Sales;Bio-feed R&D;Feed Raw Material Sales;Feed Additive Sales;Biochemical product technology research and development;Health Consulting Services(Does not include medical services);Healthy food(prepackaged)Sales;Sales of formula food for special medical purposes;food sales(Only sell prepackaged food);Food Internet Sales(Only sell prepackaged food);Food import and export;Medical Research and Experimental Development(remove human stem cells,Development and application of genetic diagnosis and treatment technology).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:food production;food sales;Food Internet Sales;Health food production;Food additive production;Production of formula food for special medical purpose;Inspection and testing service;Drug import and export;Drug retail;Drug Wholesale;Feed additive production;feed production;pharmaceutical production(Steamed Chinese Herbal Pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines);Pharmaceutical commissioned production(Steamed Chinese Herbal Pieces,saute,broil,The application of calcining and other processing technologies and the production of secret prescription products of Chinese patent medicines).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Impulse Dynamics NV develops electrical therapies for the treatment of chronic heart failure. Its product Optimizer III is designed for the treatment of patients with moderate and severe heart failure. The company was founded in 1996 and is headquartered in Willemstad, Netherlands Antilles.

Zhejiang Cancer Hospital is a Chinese private company located in Hangzhou. The firm operates as an cancer hospital.

Biovail Laboratories International SRL, a subsidiary of Bausch Health Cos., Inc., is a company headquartered in Saint Michael, Barbados, that develops, manufactures, and sells pharmaceutical products.

Dong-A Socio Holdings has been the leading pharmaceutical company in South Korea with its business focus in developing, manufacturing and distributing innovative products for the healthier life of their society. Headquartered in South Korea, Dong-A Pharm. employs over 2,300 people worldwide.

Otsuka Pharmaceutical Factory, Inc. manufactures and distributes pharmaceutical and nutritional products. Its products include medical foods, hine E-gel, processlead, engelead, innerpower, oronine h ointment, urepearl plus lotion 10 and urepearl plus cream. The company was founded on September 1, 1921 and is headquartered in Naruto, Japan.

Suzhou Fangda New Drug Development Co., Ltd., established on 2020-08-03, Business scope includes licensed projects:Inspection and testing service;Import and export;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Medical Research and Experimental Development(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Shaanxi Yuhang Electronics Co., Ltd., established on 2014-07-03, Business scope includes general items:Solar Power Technology Services;Photovoltaic equipment and components sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Wind Power Technical Services;Power Generation Technical Services;Sales of new energy original moving equipment;Wind farm related system development;Wind farm related equipment sales;electronics sales;Electronic Components Retail;Retailing of computer software, hardware and auxiliary equipment;Information system integration service;Information Technology Consulting Services;Information system operation and maintenance services;Conference and Exhibition Services;Information Consulting Service(Not including licensing information consulting services);Leather Goods Sales;Household Goods Sales;General merchandise sales;Clothing and apparel retail;paint sales(Free of Hazardous Chemicals);Sales of building decoration materials;Lighting sales;Hardware retail;furniture sales;Home Appliance Sales;needle textile sales;Arts and crafts and collectibles retail(Except for ivory and its products).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Residential interior decoration.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results)

Beijing Ailin Medical Technology Co., Ltd., established on 2018-06-22, Business scope includes technology development,Technology Promotion,technology transfer,technical consulting,Technical Services;Sell ​​self-developed products;Computer System Services;Basic software service;Application software service;software development;software consulting;product design;model design;business management;Business Management Consulting;health management,Health Advisory(Except for medical treatment activities subject to approval);Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Medical Research and Experimental Development.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

NicOx is a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glaucoma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.

Infervision is an AI high-tech company that uses deep learning technology and computer vision to help diagnose cancers. Beijing Infervision is an artificial intelligence high-tech company committed to applying deep learning technology to assist medical image diagnosis as efficient and accurate solutions. Infravision effectively uses various types of medical data to create clinically valued products and promotes precision analysis in the medical field, especially in assisted image diagnosis. Based on years of research preparation, Infervision launched the world's first "Infervision - artificial intelligence precise healthcare platform", and is the first to release intelligent X-ray assisted diagnosis products and intelligent CT assisted diagnosis products. These products are already in trials at Shanghai Changzheng Hospital, Tongji Medical College of HUST in Wuhan, and Dalian Zhongshan Hospital. The company is also engaged in academic research and has established a deep cooperative relationship with top institutions in Chinese Radiology, combining both medical science and medical technology while laying a solid foundation for artificial intelligence breakthroughs in the medical field. Infervision has established cooperative business partnerships with close to 20 Tertiary Grade A hospitals including Peking Union Medical College Hospital, Shanghai Changzheng Hospital, Tongji Medical College of HUST in Wuhan, and Dalian Zhongshan Hospital, and has successfully broken the barriers between medical data, technology, and application scenarios, creating a unique system of an artificial intelligence computing platform and precise healthcare intelligence system.

Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.

Dong-A ST Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for gastric mucous membrane protection, antihistaminic agents, ischemic improvements, antithrombotic, functional digestion, hyperlipemia cure, growth hormone, anti-peptic ulcer cure, cerebral metabolic, high blood pressure, and others. The company was founded on March 1, 2013 and is headquartered in Seoul, South Korea.